Quantum BioPharma issued a formal response to the press releases published by The Schall Law Firm and DJS Law Group on October 9th and 10th , 2025, which announced an investigation into alleged securities law violations by the Company. “The Company strongly refutes the vague and unsubstantiated claims made in the releases, which fail to specify any factual basis or concrete allegations. Specifically, the Schall Law Firm’s statement that it is “investigating claims on behalf of investors… for violations of the securities laws” and that the investigation “focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors” lacks any detail, context, or substantiation. These ambiguous assertions are misleading and appear designed to provoke unwarranted concern among shareholders,” the company said.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Launches Whistleblower Reward Amid Stock Manipulation Lawsuit
- Quantum BioPharma offers cash reward up to $7M for market manipulation proof
- Quantum BioPharma Sets Record Date for Special Dividend Linked to Litigation Proceeds
- Quantum BioPharma announces record date for special dividend distribution
- Quantum BioPharma Advances Lucid-MS with Key Study Reports